VOLITIONRX LTD 8-K

What Happened
VolitionRx Ltd (VNRX) announced that on February 6, 2026 it received a notice from the NYSE American stating the company is not in compliance with the exchange’s listing standards in Section 1003(a)(i),(ii) and (iii) regarding minimum stockholders’ equity following reported losses. The company must submit a written plan to the NYSE American by March 8, 2026 explaining how it will regain compliance by August 6, 2027. VolitionRx issued a related press release on February 9, 2026. The shares will continue trading on NYSE American under the symbol VNRX but with a “.BC” designation indicating “below compliance.”

Key Details

• Notice date: February 6, 2026; press release: February 9, 2026.
• Plan due to NYSE American by March 8, 2026; compliance target date: August 6, 2027.
• Equity thresholds cited in Section 1003(a): $2.0M, $4.0M and $6.0M depending on the company’s recent loss history.
• If the plan is accepted the company will face periodic (including quarterly) monitoring; if no plan is submitted, the plan is not accepted, or progress is insufficient, NYSE American may commence delisting proceedings. The company may appeal any delisting determination.

Why It Matters
This notice signals a material listing-risk event: failure to regain compliance could lead to delisting from NYSE American, which typically reduces liquidity and can put downward pressure on a stock’s price. For now, trading continues and the company remains subject to SEC reporting. Investors should monitor the company’s plan submission, any NYSE responses, and subsequent quarterly updates to assess the likelihood of retained listing or potential delisting.